{
    "clinical_study": {
        "@rank": "73926", 
        "arm_group": [
            {
                "arm_group_label": "Hydroxytyrosol", 
                "arm_group_type": "Experimental", 
                "description": "Hydroxytyrosol, the major polyphenol in olive oil, 40mg will be taken once per day for 6 months."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 40mg will be taken once per day for 6 months."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to conduct a double-blind, randomized controlled trial (RCT),\n      to determine if six month supplementation of olive oil can improve the health of the blood\n      vessels and improve long term health of the heart and blood vessels, in patients requiring\n      percutaneous coronary intervention (PCI)."
        }, 
        "brief_title": "Olive Oil and Cardiovascular Health", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cardiovascular Disease", 
            "Endothelial Function"
        ], 
        "condition_browse": {
            "mesh_term": "Cardiovascular Diseases"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Subjects will be included if they have all of the following\n\n          1. Age \u2265 18 years old\n\n          2. Have known diagnosis of coronary artery disease\n\n          3. Demonstrated endothelial dysfunction (reactive hyperemia - EndoPAT score < 2.0) at\n             time of screening\n\n        Patient exclusion criteria:\n\n        Patients will be excluded if they have one or more of the following:\n\n          1. Hypertension (at Screening): any patient with systolic blood pressure (SBP) \u2265 170\n             mmHg or diastolic blood pressure \u2265 110 mmHg, or hypotension (SBP < 100 mmHg)\n\n          2. Uncontrolled Diabetes Mellitus\n\n          3. Experienced an acute coronary syndrome within 3 months\n\n          4. PCI or revascularization for an acute coronary syndrome within 3 months\n\n          5. Second (II) or third (III) degree heart block without a pacemaker and/or concurrent\n             potentially life threatening arrhythmia or other uncontrolled arrhythmia\n\n          6. Congestive heart failure NYHA class III and IV\n\n          7. Unstable serum creatinine (>2.0)\n\n          8. Any surgical or medical condition which might significantly alter the absorption,\n             distribution, metabolism, or excretion of the olive oil including, but not limited\n             to, any of the following:\n\n               -  History of major gastrointestinal tract surgery such as gastrectomy,\n                  gastroenterostomy, or bowel resection\n\n               -  Any history of pancreatic injury, pancreatitis or evidence of impaired\n                  pancreatic function/injury as indicated by abnormal lipase or amylase\n\n               -  Evidence of hepatic disease as determined by a history of hepatic\n                  encephalopathy, a history of cirrhosis, esophageal varices, or a history of\n                  portocaval shunt\n\n          9. Any concurrent life threatening condition with a life expectancy less than 2 years\n\n         10. History or evidence of drug or alcohol abuse within the last 12 months\n\n         11. History of hypersensitivity to any of the study drugs or to medications belonging to\n             the same therapeutic class as the study drugs as well as known or suspected\n             contraindications to the study drugs\n\n         12. History of noncompliance to medical regimens or unwillingness to comply with the\n             study protocol\n\n         13. History of malignancy other than basal cell skin cancer within the past five years\n\n         14. Any surgical or medical condition, which in the opinion of the investigator, may\n             place the patient at higher risk from his/her participation in the study, or is\n             likely to prevent the patient from complying with the requirements of the study or\n             completing the study\n\n         15. Use of other investigational drugs at the time of enrollment, or within 30 days or 5\n             half-lives of enrollment, whichever is longer\n\n         16. Any condition that in the opinion of the investigator would jeopardize the evaluation\n             of efficacy or safety\n\n         17. Persons directly involved in the execution of this protocol\n\n         18. Pregnant or nursing (lactating) women\n\n         19. Women of child-bearing potential unless postmenopausal for at least one year,\n             surgically sterile or using effective methods of contraception as defined by local\n             Health Authorities"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01983943", 
            "org_study_id": "13-001080"
        }, 
        "intervention": [
            {
                "arm_group_label": "Hydroxytyrosol", 
                "description": "A 40mg capsule will be taken once daily for 6 months.", 
                "intervention_name": "Hydroxytyrosol, the active ingredient in olive oil.", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "A 40mg placebo will be taken once per day for 6 months.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Hydroxytyrosol", 
                    "Placebo"
                ], 
                "description": "Nutrition counseling on eating a healthy diet will be offered once at baseline.", 
                "intervention_name": "Nutrition counseling", 
                "intervention_type": "Behavioral"
            }, 
            {
                "arm_group_label": [
                    "Hydroxytyrosol", 
                    "Placebo"
                ], 
                "description": "An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.", 
                "intervention_name": "Endopat", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "3,4-dihydroxyphenylethanol", 
                "Phenylethyl Alcohol"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "November 7, 2013", 
        "location": {
            "contact": {
                "last_name": "Eric Bruhn", 
                "phone": "507-255-7100"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic in Rochester"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Hydroxytyrosol on Vascular Health", 
        "overall_contact": {
            "last_name": "Eric Bruhn", 
            "phone": "507-255-7100"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Amir Lerman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "In order to address these hypotheses, our specific aims are to investigate the effect of administration of six months of hydroxytyrosol in individuals with multiple cardiovascular risk factors and with known coronary artery disease, on: Improvement of endothelial function as determined by peripheral endothelial function testing and circulating EPCs.", 
                "measure": "Endothelial function", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }, 
            {
                "description": "In order to address these hypotheses, our specific aims are to investigate the effect of administration of six months of hydroxytyrosol in individuals with multiple cardiovascular risk factors and with known coronary artery disease, on: Improvement and normalization of surrogate markers of CVD such as leukocytes, glucose, lipids, renal function, and high-sensitivity C-reactive protein (hs-CRP).", 
                "measure": "Surrogate markers", 
                "safety_issue": "No", 
                "time_frame": "6 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01983943"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Amir Lerman", 
            "investigator_title": "Invasive Cardiologist, Professor of Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}